Review assesses efficacy and safety concerns regarding chikungunya vaccines for travelers, suggesting ongoing uncertainty.
Chikungunya vaccine recommendations remain controversial. CHIK-LA has lost its US approval. Adequate data on human vaccine efficacy for either vaccine is lacking. Live virus vaccines have inherent risks. Given early safety signals, for CHIK-LA a robust human safety dataset is lacking.
No takes yet. Share an insight, caveat, or question.
David O. Freedman (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: